Role of PARP inhibitors in cancer biology and therapy

D. Davar, J. H. Beumer, L. Hamieh, H. Tawbi

Research output: Contribution to journalReview articlepeer-review

109 Scopus citations


Deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncology heralded the clinical development of poly(ADP-ribose) polymerase (PARP) inhibitors. Although initially developed to exploit synthetic lethality in models of cancer associated with defective DNA repair, our burgeoning knowledge of PARP biology has resulted in these agents being exploited both in cancer with select chemotherapeutic agents and in non-malignant diseases. In this review article, we briefly review the mechanisms of DNA repair and pre-clinical development of PARP inhibitors before discussing the clinical development of the various PARP inhibitors in depth.

Original languageEnglish
Pages (from-to)3907-3921
Number of pages15
JournalCurrent Medicinal Chemistry
Issue number23
StatePublished - Aug 2012


  • BRCA1
  • BRCA2
  • Base excision repair (BER)
  • CEP-9722
  • DNA repair
  • GPI-21016
  • INO-1001
  • Iniparib
  • LT-673
  • MK-4827
  • Olaparib
  • Poly(ADP-ribose) polymerase (PARP) inhibitors
  • Rucaparib
  • Synthetic lethality
  • Triple negative breast cancer
  • Veliparib


Dive into the research topics of 'Role of PARP inhibitors in cancer biology and therapy'. Together they form a unique fingerprint.

Cite this